Zoetis Inc
ZTS118.660USD
+1.060+0.90%
Cierre 12/12, 16:00（ET）Cotizaciones retrasadas 15 min
52.38BCap. mercado
19.98P/E TTM
Más Datos de Zoetis Inc Compañía
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Información de Zoetis Inc
Símbolo de cotizaciónZTS
Nombre de la empresaZoetis Inc
Fecha de salida a bolsaFeb 01, 2013
Director ejecutivoPeck (Kristin C)
Número de empleados13800
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
Dirección10 Sylvan Way
CiudadPARSIPPANY
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal07054
Teléfono19738227000
Sitio Webhttps://www.zoetis.com/
Símbolo de cotizaciónZTS
Fecha de salida a bolsaFeb 01, 2013
Director ejecutivoPeck (Kristin C)
Ejecutivos de Zoetis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+0.02%
Mr. Michael B. Mccallister
Mr. Michael B. Mccallister
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.86K
-6.61%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+12.20%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Frank A. D'amelio
Mr. Frank A. D'amelio
Independent Director
Independent Director
14.81K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+0.39%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+8.28%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
2.82K
+51.75%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
2.59K
+19.25%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+0.02%
Mr. Michael B. Mccallister
Mr. Michael B. Mccallister
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.86K
-6.61%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+12.20%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Frank A. D'amelio
Mr. Frank A. D'amelio
Independent Director
Independent Director
14.81K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Parasiticides
673.00M
27.36%
Vaccines
504.00M
20.49%
Dermatology
463.00M
18.82%
Anti-infectives
219.00M
8.90%
Pain and sedation
217.00M
8.82%
Otro
384.00M
15.61%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.36B
55.12%
Other emerging markets
225.00M
9.15%
Other Developed
162.00M
6.59%
Brazil
93.00M
3.78%
Australia
83.00M
3.37%
Otro
541.00M
21.99%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Parasiticides
673.00M
27.36%
Vaccines
504.00M
20.49%
Dermatology
463.00M
18.82%
Anti-infectives
219.00M
8.90%
Pain and sedation
217.00M
8.82%
Otro
384.00M
15.61%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.55%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Otro
74.46%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.55%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Otro
74.46%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.25%
Investment Advisor/Hedge Fund
32.09%
Research Firm
4.42%
Insurance Company
3.92%
Bank and Trust
2.61%
Pension Fund
2.55%
Hedge Fund
1.56%
Sovereign Wealth Fund
1.25%
Family Office
0.15%
Otro
2.21%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
2023Q3
2966
434.04M
94.28%
-3.00M
2023Q2
2949
430.67M
93.19%
-11.77M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
41.69M
9.41%
+326.69K
+0.79%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
22.66M
5.11%
-498.13K
-2.15%
Jun 30, 2025
State Street Investment Management (US)
19.74M
4.45%
-59.31K
-0.30%
Jun 30, 2025
State Farm Insurance Companies
16.84M
3.8%
-34.10K
-0.20%
Jun 30, 2025
Geode Capital Management, L.L.C.
11.08M
2.5%
+95.29K
+0.87%
Jun 30, 2025
Wellington Management Company, LLP
8.89M
2.01%
+2.82M
+46.56%
Jun 30, 2025
Polen Capital Management, LLC
8.42M
1.9%
-375.82K
-4.27%
Jun 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
6.75M
1.52%
+4.58M
+209.96%
Jun 30, 2025
Wells Fargo Advisors
5.83M
1.32%
-180.38K
-3.00%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.17%
+131.36K
+2.60%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Pet Care ETF
9.4%
VanEck Pharmaceutical ETF
9.02%
VanEck Agribusiness ETF
7.81%
iShares U.S. Pharmaceuticals ETF
4.26%
Honeytree US Equity ETF
3.86%
First Trust NASDAQ Pharmaceuticals ETF
3.58%
Polen Capital Global Growth ETF
3.35%
State Street SPDR S&P Pharmaceuticals ETF
2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
2.47%
Themes US R&D Champions ETF
1.96%
Ver más
ProShares Pet Care ETF
Proporción9.4%
VanEck Pharmaceutical ETF
Proporción9.02%
VanEck Agribusiness ETF
Proporción7.81%
iShares U.S. Pharmaceuticals ETF
Proporción4.26%
Honeytree US Equity ETF
Proporción3.86%
First Trust NASDAQ Pharmaceuticals ETF
Proporción3.58%
Polen Capital Global Growth ETF
Proporción3.35%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
Proporción2.47%
Themes US R&D Champions ETF
Proporción1.96%
Dividendos
Un total de
2.94B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Oct 09, 2025
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
Oct 31, 2025
Dec 02, 2025
Oct 31, 2025
May 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
Jul 18, 2025
Sep 03, 2025
Jul 18, 2025
Feb 06, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
Apr 21, 2025
Jun 03, 2025
Apr 21, 2025
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
Oct 12, 2023
ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023
Nov 01, 2023
Dec 01, 2023
Oct 31, 2023
May 11, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Sep 01, 2023 going ex on Jul 20, 2023
Jul 21, 2023
Sep 01, 2023
Jul 20, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Zoetis Inc?
Los cinco principales accionistas de Zoetis Inc son:
The Vanguard Group, Inc. posee 41.69M acciones, lo que representa el 9.41% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 22.66M acciones, lo que representa el 5.11% del total de acciones.
State Street Investment Management (US) posee 19.74M acciones, lo que representa el 4.45% del total de acciones.
State Farm Insurance Companies posee 16.84M acciones, lo que representa el 3.80% del total de acciones.
Geode Capital Management, L.L.C. posee 11.08M acciones, lo que representa el 2.50% del total de acciones.
The Vanguard Group, Inc. posee 41.69M acciones, lo que representa el 9.41% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 22.66M acciones, lo que representa el 5.11% del total de acciones.
State Street Investment Management (US) posee 19.74M acciones, lo que representa el 4.45% del total de acciones.
State Farm Insurance Companies posee 16.84M acciones, lo que representa el 3.80% del total de acciones.
Geode Capital Management, L.L.C. posee 11.08M acciones, lo que representa el 2.50% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Zoetis Inc?
Los tres principales tipos de accionista de Zoetis Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Zoetis Inc (ZTS)?
A fecha de 2025Q3, 3275 instituciones poseen acciones de Zoetis Inc, con un valor de mercado combinado de aproximadamente 435.62M, lo que representa el 98.29% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 0.29%.
¿Cuál es la mayor fuente de ganancias de Zoetis Inc?
El FY2025Q2, el segmento empresarial Parasiticides generó la ganancia más alta para Zoetis Inc, ascendiendo a 673.00M y representando el 27.36% de la ganancia total.
